When It Comes To Antibody Technology, Pfizer's On The Prowl
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's latest partnership in the space is with Theraclone Sciences, a Seattle start-up with an antibody technology that uses human B cells.
You may also be interested in...
A Goliath Grows: Pfizer To Buy Wyeth For $68 Billion
Pfizer aims to acquire rival Wyeth in a proposed deal valued at approximately $68 billion, broadening Pfizer's leadership position in the market by creating a drug powerhouse with combined sales of more than $71 billion, based on 2008 revenues
Bonny Deal: Wyeth Acquires Scottish Drug Discovery Firm Haptogen
Firm hopes to use Haptogen’s technology to generate novel protein therapeutics that can be made orally bioavailable, VP-Biologic Technologies Projan tells “The Pink Sheet” DAILY.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.